Akeso, Inc. (HKG:9926)

Hong Kong · Delayed Price · Currency is HKD

130.30

-0.70 (-0.53%)

Sep 19, 2025, 10:37 AM HKT

Akeso Employees

Akeso had 3,035 employees as of December 31, 2024. The number of employees increased by 257 or 9.25% compared to the previous year.

Employees

3,035

Change (1Y)

257

Growth (1Y)

9.25%

Revenue / Employee

779.60K HKD

Profits / Employee

-262.69K HKD

Market Cap

120.67B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	3,035	257	9.25%
Dec 31, 2023	2,778	437	18.67%
Dec 31, 2022	2,341	476	25.52%
Dec 31, 2021	1,865	1,119	150.00%
Dec 31, 2020	746	356	91.28%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
BeOne Medicines AG	11,000
JD Health International	3,564
Hansoh Pharmaceutical Group Company	8,989
Innovent Biologics	5,659
WuXi Biologics	12,575
Sino Biopharmaceutical	24,379
Sichuan Kelun-Biotech Biopharmaceutical	1,837
CSPC Pharmaceutical Group	21,400

Employee Rankings

Akeso News

3 days ago - Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia - Nasdaq
10 days ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
22 days ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
22 days ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus
22 days ago - Akeso shares surge as cancer drug achieves key milestone in China trial - Seeking Alpha
3 months ago - Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback - South China Morning Post
5 months ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
5 months ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post